Lopital strengthens its position through the acquisition of Culsana
Amsterdam, Oisterwijk, 15 June 2026 – Our portfolio company Lopital, a developer and supplier of innovative hygiene, transfer, and mobility solutions for the healthcare sector, has acquired Culsana. Through this strategic add-on acquisition, Lopital further expands its product portfolio and strengthens its position within the institutional healthcare market.
Joining Forces to Support Lopital’s Growth Strategy
Culsana develops and supplies medical seating and positioning support solutions for hospitals, healthcare institutions, and other public healthcare organizations. Since its founding in 2011, the company has built a strong position within the Dutch healthcare market.
Jan van Megen, CEO of Lopital: “With the addition of Culsana, we create immediate commercial synergies through our complementary product portfolios and shared customer base. This acquisition fits perfectly within our buy-and-build strategy, through which we continue to expand our offering with proprietary, complementary products for the healthcare sector.”
Since 2023, Holland Capital has supported Lopital as a shareholder in the company’s continued growth, both organically and through targeted acquisitions. The acquisition of Culsana marks another step in this strategy and contributes to Lopital’s further development as a leading partner for healthcare institutions in the Netherlands and abroad.
About Culsana
Founded in 2011 and headquartered in Schinnen, Culsana develops and supplies medical seating and positioning support solutions for hospitals, healthcare institutions, and other public healthcare organizations.
About Lopital
Founded in 1977, Lopital operates from its headquarters in Oisterwijk and is active in more than 25 countries. The company develops, assembles, and supplies high-quality hygiene, transfer, and mobility solutions for the healthcare sector./medexs.com/
About Holland Capital
For more than 40 years, Holland Capital has been investing responsibly and successfully in ambitious small and medium-sized enterprises (SMEs) in the Benelux and Germany. With offices in Amsterdam and Düsseldorf, Holland Capital focuses through specialized sector teams on the Healthcare and Technology sectors.
Highcare ondersteunt management buy-out zorgzuster
Roosendaal/Maastricht, 27 november 2018 - Highcare en Ralph Smeets, nemen alle aandelen in Zorgzuster Nederland over van Start People (onderdeel van USG People The Netherlands). Ralph Smeets heeft in 2010 Zorgzuster opgericht. Highcare is het uitzend- en...
Holland Venture investeert in WSO2 integrator Yenlo
Amsterdam, 19 november 2018 – Participatiemaatschappij Holland Venture investeert in Yenlo, dé integratiespecialist op het gebied van WSO2 open source middleware technologie. Het management en aandeelhouders hebben zich ten doel gesteld de komende jaren de groei van...
Investeerder Holland Venture start nieuw fonds voor innovaties in de zorg
Amsterdam, 20 september 2018 – Holland Venture is een nieuw zorginnovatie fonds gestart dat de komende jaren gaat investeren in circa 10 innovatieve ondernemers in de zorg. Het doel van het fonds is om ondernemers die actief zijn op het gebied van medical devices,...
Holland Venture investeert in LivAssured voor ontwikkeling NightWatch
Amsterdam, 20 september 2018 – Investeringsmaatschappij Holland Venture investeert met Oost NL en Health Innovations Fund in het bedrijf LivAssured, dat de revolutionaire NightWatch heeft ontwikkeld in samenwerking met neurologen en patiëntenverenigingen. De...
Quantib presenteert revolutionaire software voor ondersteuning en tracking van dementie en MS-diagnose
Rotterdam, Nederland, 1 augustus 2018 - Quantib, marktleider in hulpmiddelen voor kunstmatige intelligentie voor radiologie, heeft een belangrijke upgrade van hun dementie en MS-diagnose-ondersteuningssoftware Quantib ™ ND uitgebracht. Een substantiële lijst met...
MedAngel neemt twijfels over werkzaamheid medicatie weg
Digitale healthcare start-up ontvangt investering van Holland Venture en Oost NL Apeldoorn/Amsterdam, 13 juli 2018 - Onzekerheid over de werking van je medicijnen, geen controle hebben over hoe je dag loopt, het houdt veel chronisch zieke patiënten bezig. Er zijn...
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Inselstraße 34
40479 Düsseldorf
+49 (0) 211 43 63 69 01
info@hollandcapital.nl